TCT 2010 Late Breaking Trials To Have Impact On Practice Of Interventional Cardiology
Clinical trials in a variety of areas within interventional cardiovascular medicine that will be presented at TCT 2010 will directly affect the way that people with cardiovascular disease are treated. Breakthroughs in science and medical research, presented exclusively at TCT, will lead to new treatments that are minimally invasive and involve shorter recovery times. Among the topics being covered are stenting in the femoral artery, polymer-free drug-eluting stents, valves and drug-eluting balloons used in angioplasty... (Source: Health News from Medical News Today)
CytRx Initiates Phase 2 Clinical Trial With Bafetinib In Advanced Prostate Cancer
CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, today announced initiation of the PROstate Advanced Cancer Treatment (PROACT) Phase 2 proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib in patients with advanced prostate cancer. The open-label PROACT trial is being conducted at City of Hope, located just outside of Los Angeles, California, as well as multiple clinical sites in India... (Source: Health News from Medical News Today)
